Issue link: https://htpgraphics.uberflip.com/i/1055210
INNOVATION CENTRE Occupancy levels remain high with an average of 97% over the last year. UMIC continues to liaise with tenants to offer a series of events which will benefit them, events around funding and investment possibilities are planned for the coming year. We are also planning an estate wide Christmas Networking Event which will be showcased in our new Atrium Lounge. Our traditional Biosciences tenants continue to do well and this year has seen Cellular Therapeutics change name to Immetacyte and continue to grow. Below is a brief overview provided by Immetacyte. 2017/2018 has been a busy year for us. In the past year we have changed our name from Cellular Therapeutics to Immetacyte, we have been busy with contracts for development of manufacturing processes for our customers and we have been successful in securing more than £5M of grant funding for new projects to be spent on the development, commercialisation and licensing our TIL product. In response to these successes, the company has doubled in head count, employing managers, scientists in R&D and GMP manufacture as well as administrative staff. It is an extremely exciting time for us. In the year to come we will continue to grow our R&D and GMP manufacturing departments and begin clinical trials in our cell therapy product - TIL. We will be taking on new units in the building to meet the demands of our working schedule. UMIC has also welcomed the Royal College of Surgeons to the CTF building this year, we are delighted that they chose the Innovation Centre as their first base outside of London. UMIC's £1.3 million pound refurbishment plan is now well underway. The Atrium Lounge is now completed, the business hub which will house new start-ups is due to open this month and extensive repairs and renewals to the buildings are in progress.